



## Company Overview

Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration.

[Sign up here](#) to receive notices about press releases and SEC filings.

## Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Aug 5 2025, 7:00 AM EDT

## Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 29 2025, 8:00 AM EDT

## Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 2 2025, 4:30 PM EDT

## Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	27.82m
Last Price	\$0.6954
52-Week	\$0.68 - \$3.02

08/05/2025 08:00 PM EDT

## Investor Relations

[ir@iterumtx.com](mailto:ir@iterumtx.com)

## Management Team

### Corey N. Fishman

Chief Executive Officer

### Judith M. Matthews

Chief Financial Officer

### Christine R. Coyne, MBA

Chief Commercial Officer

### Tom Loughman, PhD

Senior Vice President, Technical Operations

### Steven I. Aronin, MD

Senior Vice President and Head of Clinical Development

## Iterum Therapeutics plc

200 S Wacker Drive  
Suite 3100  
Chicago, IL 60606  
USA

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.